<DOC>
	<DOCNO>NCT02666755</DOCNO>
	<brief_summary>The purpose study investigate sensitivity，specificity concordance rate EGFR test result plasma comparison result match tumor tissue test amplification refractory mutation system ( ARMS ) . Moreover , investigator correlate finding plasma survival advanced patient .</brief_summary>
	<brief_title>Novel Detection System Lung Cancer Curative Effect Monitoring</brief_title>
	<detailed_description>Non-small cell lung cancer ( NSCLC ) , account 80 % lung cancer , lead cause cancer death worldwide . Inhibition epidermal growth factor receptor ( EGFR ) kinase activity EGFR tyrosine kinase inhibitor , gefitinib erlotinib , result improve response prolong progression-free survival ( PFS ) select non-small cell lung cancer ( NSCLC ) patient harbor sensitize EGFR mutation , especially exon 19del exon 21（L858R） mutation . Unfortunately , 50 % -60 % patient accept EGFR tyrosine kinase inhibitor sensitize mutation receive resistance mutation , T790M resistance target active pharmaceutical development . So EGFR mutation test step identify right patient EGFR tyrosine kinase inhibitor treatment . Now tissue sample tumor cytologic sample accept appropriate sample type EGFR mutation detection , sample always available diagnosis , , even available , may insufficient quality quantity mutation test . Noninvasive technique tumor genotyping may need fully realize , plasma sample . Cell-free DNA ( cf-DNA ) plasma kind fresh realtime sample , show promising detection sensitize EGFR mutation even resistance mutation（T790M ) . However , challenge also raise detect low abundance mutant alleles plasma . In study Droplet Digital polymerase chain reaction Realtime polymerase chain reaction use assess EGFR mutation plasma DNA sample patient advanced NSCLC EGFR tyrosine kinase inhibitor therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Aged 1885 year old ; 2 . The diagnosis lung cancer pathological examination ; 3 . At least one specific measurable lung cancer lesion ( accord RECIST criterion , application spiral CT , lesion diameter 10 mm high ) ; 4 . People understand willing accept study , sign inform consent 1 . With severe hemorrhagic disease ; 2 . Compliance poor , ca n't cooperate visitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lung Neoplasms digital polymerase chain reaction</keyword>
</DOC>